1UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland. 2Systems Biology Ireland, UCD School of Medicine, University College Dublin, ...

1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington. 2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.

Cancer Res (2023) 83 (7_Supplement): ND02.

A committee of three scientists named by the CEBP Editor-in-Chief selects the Award winner each year based on the committee’s evaluation of the following criteria: originality; scientific, clinical, ...

1Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 2Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, ...

Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing, China.

1Yonsei University, College of Medicine, Seoul, Republic of Korea.

Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain. Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), ...

Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...

1Baylor College of Medicine, Houston, TX.

Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer.

1Department of Oncology, University of Lausanne, Lausanne, Switzerland.